name,title,company,location,company_hq,email,linkedin,recent_publication,publication_year,publication_title,company_funding,uses_3d_models,tenure_months,propensity_score,rank
Dr. Lisa Kumar,VP Safety Assessment,Merck,"Cambridge, MA","Cambridge, MA",lisa.kumar@merck.com,linkedin.com/in/lisakumar,True,2024.0,Advanced in vitro toxicity testing methods,Series C,True,16,100,1
Dr. Jessica Smith,Toxicology Manager,Novartis,"Basel, Switzerland","Basel, Switzerland",jessica.smith@novartis.com,linkedin.com/in/jessicasmith,True,2023.0,Drug-induced liver injury prediction using spheroids,Series C,True,20,100,1
Dr. Thomas Garcia,Safety Pharmacology Lead,CRISPR Therapeutics,"Basel, Switzerland","Basel, Switzerland",thomas.garcia@crisprtherap.com,linkedin.com/in/thomasgarcia,True,2024.0,3D cell culture models in safety pharmacology,Series B,False,20,100,1
Dr. Jennifer Miller,Principal Scientist - Toxicology,Roche,"Basel, Switzerland","Basel, Switzerland",jennifer.miller@roche.com,linkedin.com/in/jennifermiller,True,2024.0,Liver organoid applications in drug discovery,Series C,False,20,100,1
Dr. Michelle Davis,Senior Director - Nonclinical Safety,Ginkgo Bioworks,"Cambridge, MA","Cambridge, MA",michelle.davis@ginkgobiowor.com,linkedin.com/in/michelledavis,True,2023.0,Liver organoid applications in drug discovery,Series C,True,21,100,1
Dr. Maria Garcia,Director of Safety Sciences,Sanofi,"Cambridge, MA","Cambridge, MA",maria.garcia@sanofi.com,linkedin.com/in/mariagarcia,True,2023.0,Novel 3D hepatic models for DILI assessment,Series B,False,55,100,1
Dr. Laura Garcia,Group Leader - Toxicology,Vertex Pharmaceuticals,New Jersey,New Jersey,laura.garcia@vertex.com,linkedin.com/in/lauragarcia,True,2024.0,Novel 3D hepatic models for DILI assessment,Series C,True,42,96,7
Dr. Maria Williams,Director of Safety Sciences,AstraZeneca,"San Diego, CA","San Diego, CA",maria.williams@astrazeneca.com,linkedin.com/in/mariawilliams,True,2023.0,Microphysiological systems for toxicity prediction,Series C,False,38,96,7
Dr. Brian Williams,Director of Toxicology,Alnylam Pharmaceuticals,"Oxford, UK","Oxford, UK",brian.williams@alnylam.com,linkedin.com/in/brianwilliams,True,2023.0,Drug-induced liver injury prediction using spheroids,Series C,True,22,96,7
Dr. Laura Johnson,Director of Safety Sciences,Merck,"South San Francisco, CA","South San Francisco, CA",laura.johnson@merck.com,linkedin.com/in/laurajohnson,True,2023.0,Microphysiological systems for toxicity prediction,Series A,False,53,96,7
Dr. Robert Lee,Principal Scientist - Toxicology,Vertex Pharmaceuticals,"Seattle, WA","Seattle, WA",robert.lee@vertex.com,linkedin.com/in/robertlee,True,2023.0,High-throughput screening using 3D models,Series C,True,56,96,7
Dr. Betty Smith,Toxicology Manager,Merck,"London, UK","London, UK",betty.smith@merck.com,linkedin.com/in/bettysmith,True,2023.0,NAMs for hepatotoxicity screening,Series B,False,26,96,7
Dr. James Jones,Senior Director - Nonclinical Safety,CRISPR Therapeutics,"London, UK","London, UK",james.jones@crisprtherap.com,linkedin.com/in/jamesjones,True,2024.0,3D cell culture models in safety pharmacology,Series B,True,52,96,7
Dr. Robert Taylor,Director of Safety Sciences,Bayer,"Seattle, WA","Seattle, WA",robert.taylor@bayer.com,linkedin.com/in/roberttaylor,True,2023.0,Advanced in vitro toxicity testing methods,Series A,True,41,96,7
Dr. Daniel Martin,Group Leader - Toxicology,Editas Medicine,"Research Triangle Park, NC","Research Triangle Park, NC",daniel.martin@editasmedici.com,linkedin.com/in/danielmartin,True,2023.0,3D cell culture models in safety pharmacology,Series C,False,28,92,15
Dr. Jennifer Harris,Director of Safety Sciences,Regeneron,"Boston, MA","Boston, MA",jennifer.harris@regeneron.com,linkedin.com/in/jenniferharris,True,2023.0,Predictive toxicology with in vitro systems,Series C,False,34,92,15
Dr. James Park,Head of Preclinical Safety,Johnson & Johnson,"South San Francisco, CA","South San Francisco, CA",james.park@johnson&john.com,linkedin.com/in/jamespark,True,2024.0,Novel 3D hepatic models for DILI assessment,Public,True,14,92,15
Dr. Karen Rodriguez,Safety Pharmacology Lead,BioMarin,Remote - Texas,Remote - Texas,karen.rodriguez@biomarin.com,linkedin.com/in/karenrodriguez,True,2023.0,Microphysiological systems for toxicity prediction,Series C,True,59,92,15
Dr. Brian Harris,Director of Toxicology,Novo Nordisk,"London, UK","London, UK",brian.harris@novonordisk.com,linkedin.com/in/brianharris,True,2024.0,NAMs for hepatotoxicity screening,IPO,False,34,92,15
Dr. Jessica Martin,Principal Scientist - Toxicology,Alexion,"Oxford, UK","Oxford, UK",jessica.martin@alexion.com,linkedin.com/in/jessicamartin,True,2023.0,Liver organoid applications in drug discovery,Public,False,40,92,15
Dr. Matthew White,Safety Pharmacology Lead,Bayer,"Seattle, WA","Seattle, WA",matthew.white@bayer.com,linkedin.com/in/matthewwhite,True,2023.0,Novel 3D hepatic models for DILI assessment,Public,True,8,92,15
Dr. Kevin Miller,VP Safety Assessment,Pfizer,"Seattle, WA","Seattle, WA",kevin.miller@pfizer.com,linkedin.com/in/kevinmiller,True,2023.0,Novel 3D hepatic models for DILI assessment,Public,False,30,92,15
Dr. Betty Davis,Principal Scientist - Toxicology,Alexion,New Jersey,New Jersey,betty.davis@alexion.com,linkedin.com/in/bettydavis,True,2023.0,Advanced in vitro toxicity testing methods,Public,False,54,92,15
Dr. James Brown,Senior Director - Nonclinical Safety,Takeda,"Seattle, WA","Seattle, WA",james.brown@takeda.com,linkedin.com/in/jamesbrown,True,2023.0,Advanced in vitro toxicity testing methods,IPO,True,46,92,15
Dr. Matthew Moore,Safety Pharmacology Lead,Takeda,New Jersey,New Jersey,matthew.moore@takeda.com,linkedin.com/in/matthewmoore,True,2023.0,High-throughput screening using 3D models,Public,True,57,92,15
Dr. Daniel Park,Director of Safety Sciences,Beam Therapeutics,Remote - California,Remote - California,daniel.park@beamtherapeu.com,linkedin.com/in/danielpark,True,2024.0,Liver organoid applications in drug discovery,Series C,False,13,92,15
Dr. Robert Johnson,Head of Preclinical Safety,Biogen,"Indianapolis, IN","Indianapolis, IN",robert.johnson@biogen.com,linkedin.com/in/robertjohnson,True,2023.0,Drug-induced liver injury prediction using spheroids,Series A,True,42,92,15
Dr. Robert Brown,Group Leader - Toxicology,Ginkgo Bioworks,New Jersey,New Jersey,robert.brown@ginkgobiowor.com,linkedin.com/in/robertbrown,True,2023.0,High-throughput screening using 3D models,Public,True,47,92,15
Dr. David Williams,Principal Scientist - Toxicology,Johnson & Johnson,"Boston, MA","Boston, MA",david.williams@johnson&john.com,linkedin.com/in/davidwilliams,True,2024.0,Organ-on-chip technology in drug development,Series B,False,57,92,15
Dr. Michelle Park,Senior Director - Nonclinical Safety,Merck,"Seattle, WA","Seattle, WA",michelle.park@merck.com,linkedin.com/in/michellepark,True,2023.0,Drug-induced liver injury prediction using spheroids,Public,False,25,92,15
Dr. Amanda Davis,Group Leader - Toxicology,Pfizer,"Cambridge, UK","Cambridge, UK",amanda.davis@pfizer.com,linkedin.com/in/amandadavis,True,2024.0,3D cell culture models in safety pharmacology,Public,False,46,92,15
Dr. Matthew Johnson,Group Leader - Toxicology,Roche,"Indianapolis, IN","Indianapolis, IN",matthew.johnson@roche.com,linkedin.com/in/matthewjohnson,True,2024.0,3D cell culture models in safety pharmacology,Series B,True,22,92,15
Dr. Thomas Smith,Director of Safety Sciences,Intellia Therapeutics,"Chicago, IL","Chicago, IL",thomas.smith@intelliather.com,linkedin.com/in/thomassmith,True,2023.0,Drug-induced liver injury prediction using spheroids,Series C,False,31,92,15
Dr. Christopher Mitchell,Senior Director - Nonclinical Safety,CRISPR Therapeutics,"Research Triangle Park, NC","Research Triangle Park, NC",christopher.mitchell@crisprtherap.com,linkedin.com/in/christophermitchell,True,2024.0,Microphysiological systems for toxicity prediction,Series B,False,9,92,15
Dr. Jennifer Lee,Lead Toxicologist,Roche,"Basel, Switzerland","Basel, Switzerland",jennifer.lee@roche.com,linkedin.com/in/jenniferlee,True,2023.0,High-throughput screening using 3D models,Series B,False,30,91,35
Dr. Andrew Moore,Associate Director - Safety,Amgen,Remote - Colorado,Remote - Colorado,andrew.moore@amgen.com,linkedin.com/in/andrewmoore,True,2024.0,High-throughput screening using 3D models,Public,True,30,88,36
Dr. Thomas Brown,Safety Pharmacology Lead,CRISPR Therapeutics,"Research Triangle Park, NC","Research Triangle Park, NC",thomas.brown@crisprtherap.com,linkedin.com/in/thomasbrown,True,2024.0,Microphysiological systems for toxicity prediction,IPO,True,21,88,36
Dr. Nancy Young,Group Leader - Toxicology,Bluebird Bio,"South San Francisco, CA","South San Francisco, CA",nancy.young@bluebirdbio.com,linkedin.com/in/nancyyoung,True,2024.0,Organ-on-chip technology in drug development,Series B,True,49,88,36
Dr. Andrew Chen,Principal Scientist - Toxicology,Bayer,"Research Triangle Park, NC","Research Triangle Park, NC",andrew.chen@bayer.com,linkedin.com/in/andrewchen,True,2023.0,Liver organoid applications in drug discovery,Public,True,7,88,36
Dr. Jessica Davis,Safety Pharmacology Lead,Sanofi,"London, UK","London, UK",jessica.davis@sanofi.com,linkedin.com/in/jessicadavis,True,2024.0,Organ-on-chip technology in drug development,Series B,False,6,88,36
Dr. Karen Johnson,Head of Preclinical Safety,Takeda,Remote - California,Remote - California,karen.johnson@takeda.com,linkedin.com/in/karenjohnson,True,2024.0,Advanced in vitro toxicity testing methods,Public,True,25,88,36
Dr. Michelle Smith,Principal Scientist - Toxicology,Ginkgo Bioworks,"Research Triangle Park, NC","Research Triangle Park, NC",michelle.smith@ginkgobiowor.com,linkedin.com/in/michellesmith,True,2023.0,NAMs for hepatotoxicity screening,Public,False,39,88,36
Dr. Steven Park,Senior Director - Nonclinical Safety,AstraZeneca,"New York, NY","New York, NY",steven.park@astrazeneca.com,linkedin.com/in/stevenpark,True,2023.0,Liver organoid applications in drug discovery,IPO,False,17,88,36
Dr. Steven Miller,VP Safety Assessment,AstraZeneca,"Cambridge, UK","Cambridge, UK",steven.miller@astrazeneca.com,linkedin.com/in/stevenmiller,True,2024.0,Organ-on-chip technology in drug development,Series C,True,20,88,36
Dr. Maria Martin,Head of Preclinical Safety,GSK,"New York, NY","New York, NY",maria.martin@gsk.com,linkedin.com/in/mariamartin,True,2023.0,3D cell culture models in safety pharmacology,Public,False,22,88,36
Dr. Matthew Rodriguez,Group Leader - Toxicology,Biogen,"San Francisco, CA","San Francisco, CA",matthew.rodriguez@biogen.com,linkedin.com/in/matthewrodriguez,True,2024.0,Organ-on-chip technology in drug development,IPO,True,49,84,46
Dr. Kevin Park,Toxicology Manager,Editas Medicine,Remote - Texas,Remote - Texas,kevin.park@editasmedici.com,linkedin.com/in/kevinpark,True,2023.0,Organ-on-chip technology in drug development,Series B,True,6,84,46
Dr. Karen Harris,Director of Toxicology,Takeda,"Chicago, IL","Chicago, IL",karen.harris@takeda.com,linkedin.com/in/karenharris,True,2024.0,Predictive toxicology with in vitro systems,Series C,False,56,84,46
Dr. Karen Park,Principal Scientist - Toxicology,Intellia Therapeutics,Remote - Colorado,Remote - Colorado,karen.park@intelliather.com,linkedin.com/in/karenpark,True,2024.0,Organ-on-chip technology in drug development,Series B,False,34,84,46
Dr. Steven Young,Safety Pharmacology Lead,Biogen,"Cambridge, UK","Cambridge, UK",steven.young@biogen.com,linkedin.com/in/stevenyoung,True,2024.0,3D cell culture models in safety pharmacology,Seed,False,54,84,46
Dr. Betty Brown,Head of Preclinical Safety,Eli Lilly,"Philadelphia, PA","Philadelphia, PA",betty.brown@elililly.com,linkedin.com/in/bettybrown,True,2024.0,Predictive toxicology with in vitro systems,Series B,True,20,84,46
Dr. Steven Chen,Associate Director - Safety,Regeneron,"Philadelphia, PA","Philadelphia, PA",steven.chen@regeneron.com,linkedin.com/in/stevenchen,True,2024.0,Organ-on-chip technology in drug development,Series B,True,30,84,46
Dr. Jessica Martin,Lead Toxicologist,AbbVie,Remote - Texas,Remote - Texas,jessica.martin@abbvie.com,linkedin.com/in/jessicamartin,True,2023.0,Liver organoid applications in drug discovery,Series B,False,55,83,53
Dr. Susan Chen,Lead Toxicologist,Intellia Therapeutics,"Chicago, IL","Chicago, IL",susan.chen@intelliather.com,linkedin.com/in/susanchen,True,2024.0,Liver organoid applications in drug discovery,Series C,True,18,83,53
Dr. David Wilson,Principal Investigator,AstraZeneca,"Cambridge, MA","Cambridge, MA",david.wilson@astrazeneca.com,linkedin.com/in/davidwilson,True,2023.0,Organ-on-chip technology in drug development,Series C,True,7,83,53
Dr. James Mitchell,Director of Toxicology,Vertex Pharmaceuticals,"Cambridge, MA","Cambridge, MA",james.mitchell@vertex.com,linkedin.com/in/jamesmitchell,True,2022.0,Drug-induced liver injury prediction using spheroids,Series C,False,23,80,56
Dr. Betty Wilson,Toxicology Manager,Bristol Myers Squibb,"Research Triangle Park, NC","Research Triangle Park, NC",betty.wilson@bristolmyers.com,linkedin.com/in/bettywilson,True,2024.0,Predictive toxicology with in vitro systems,Public,True,16,80,56
Dr. Susan Johnson,Director of Safety Sciences,Novartis,"Indianapolis, IN","Indianapolis, IN",susan.johnson@novartis.com,linkedin.com/in/susanjohnson,True,2023.0,Organ-on-chip technology in drug development,IPO,True,39,80,56
Dr. Robert Kumar,Lead Toxicologist,Novo Nordisk,"Chicago, IL","Chicago, IL",robert.kumar@novonordisk.com,linkedin.com/in/robertkumar,True,2024.0,NAMs for hepatotoxicity screening,Public,True,34,79,59
Dr. Matthew Mitchell,Research Fellow,Merck,"Cambridge, MA","Cambridge, MA",matthew.mitchell@merck.com,linkedin.com/in/matthewmitchell,True,2023.0,Liver organoid applications in drug discovery,Series C,True,57,76,60
Dr. Thomas Lee,Associate Director - Safety,Vertex Pharmaceuticals,"Oxford, UK","Oxford, UK",thomas.lee@vertex.com,linkedin.com/in/thomaslee,True,2022.0,Liver organoid applications in drug discovery,Series B,True,57,76,60
Dr. Thomas Martinez,Director of Toxicology,Novartis,"San Diego, CA","San Diego, CA",thomas.martinez@novartis.com,linkedin.com/in/thomasmartinez,True,2022.0,3D cell culture models in safety pharmacology,Series C,False,45,76,60
Dr. Betty Davis,Research Fellow,Novartis,"Boston, MA","Boston, MA",betty.davis@novartis.com,linkedin.com/in/bettydavis,True,2024.0,Advanced in vitro toxicity testing methods,Series C,True,16,76,60
Dr. Maria Martinez,Associate Director - Safety,Johnson & Johnson,"San Diego, CA","San Diego, CA",maria.martinez@johnson&john.com,linkedin.com/in/mariamartinez,True,2022.0,Novel 3D hepatic models for DILI assessment,Series A,False,51,76,60
Dr. Andrew Wilson,Staff Scientist - DMPK,Editas Medicine,"Cambridge, MA","Cambridge, MA",andrew.wilson@editasmedici.com,linkedin.com/in/andrewwilson,True,2024.0,High-throughput screening using 3D models,Series B,False,7,76,60
Dr. Andrew Park,Director of Toxicology,Bristol Myers Squibb,"South San Francisco, CA","South San Francisco, CA",andrew.park@bristolmyers.com,linkedin.com/in/andrewpark,True,2024.0,Organ-on-chip technology in drug development,Seed,False,26,76,60
Dr. Andrew Davis,Safety Pharmacology Lead,BioMarin,"Boston, MA","Boston, MA",andrew.davis@biomarin.com,linkedin.com/in/andrewdavis,True,2022.0,High-throughput screening using 3D models,Public,False,22,76,60
Dr. Nancy Garcia,Associate Director - Safety,Biogen,"Boston, MA","Boston, MA",nancy.garcia@biogen.com,linkedin.com/in/nancygarcia,True,2022.0,Novel 3D hepatic models for DILI assessment,Public,False,42,76,60
Dr. Robert Harris,Scientist II - Safety Assessment,Moderna Therapeutics,"South San Francisco, CA","South San Francisco, CA",robert.harris@modernathera.com,linkedin.com/in/robertharris,True,2022.0,Drug-induced liver injury prediction using spheroids,Series C,False,36,76,60
Dr. Matthew Park,Associate Director - Safety,Sanofi,"Oxford, UK","Oxford, UK",matthew.park@sanofi.com,linkedin.com/in/matthewpark,True,2022.0,Microphysiological systems for toxicity prediction,Series B,False,46,76,60
Dr. Nancy Moore,Director of Safety Sciences,Biogen,"Cambridge, UK","Cambridge, UK",nancy.moore@biogen.com,linkedin.com/in/nancymoore,True,2022.0,Drug-induced liver injury prediction using spheroids,Series B,True,16,76,60
Dr. Kevin Thompson,Scientist II - Safety Assessment,Roche,"Oxford, UK","Oxford, UK",kevin.thompson@roche.com,linkedin.com/in/kevinthompson,True,2022.0,Liver organoid applications in drug discovery,Series C,True,15,76,60
Dr. Emily Jones,Head of Preclinical Safety,Eli Lilly,"San Francisco, CA","San Francisco, CA",emily.jones@elililly.com,linkedin.com/in/emilyjones,True,2022.0,High-throughput screening using 3D models,Series A,True,47,76,60
Dr. Betty Harris,Toxicology Manager,Sanofi,"San Diego, CA","San Diego, CA",betty.harris@sanofi.com,linkedin.com/in/bettyharris,True,2022.0,NAMs for hepatotoxicity screening,Series B,False,32,76,60
Dr. Sarah Wilson,Senior Director - Nonclinical Safety,BioMarin,"Basel, Switzerland","Basel, Switzerland",sarah.wilson@biomarin.com,linkedin.com/in/sarahwilson,True,2022.0,Drug-induced liver injury prediction using spheroids,Public,True,25,76,60
Dr. Jessica Park,Toxicology Manager,CRISPR Therapeutics,"South San Francisco, CA","South San Francisco, CA",jessica.park@crisprtherap.com,linkedin.com/in/jessicapark,True,2022.0,Drug-induced liver injury prediction using spheroids,Series C,False,26,76,60
Dr. Andrew White,Lead Toxicologist,Beam Therapeutics,"London, UK","London, UK",andrew.white@beamtherapeu.com,linkedin.com/in/andrewwhite,True,2024.0,3D cell culture models in safety pharmacology,Seed,True,34,75,77
Dr. Jennifer Moore,Lead Toxicologist,Amgen,"London, UK","London, UK",jennifer.moore@amgen.com,linkedin.com/in/jennifermoore,True,2023.0,High-throughput screening using 3D models,Seed,False,18,75,77
Dr. Andrew Thompson,Toxicology Manager,Alexion,Remote - Colorado,Remote - Colorado,andrew.thompson@alexion.com,linkedin.com/in/andrewthompson,True,2022.0,Novel 3D hepatic models for DILI assessment,Series B,True,51,72,79
Dr. Susan Harris,Director of Toxicology,Gilead Sciences,Remote - Colorado,Remote - Colorado,susan.harris@gileadscienc.com,linkedin.com/in/susanharris,True,2022.0,NAMs for hepatotoxicity screening,Series C,True,54,72,79
Dr. Amanda Rodriguez,Toxicology Manager,Biogen,"New York, NY","New York, NY",amanda.rodriguez@biogen.com,linkedin.com/in/amandarodriguez,True,2022.0,Novel 3D hepatic models for DILI assessment,Series B,True,42,72,79
Dr. Amanda Garcia,Associate Director - Safety,Alnylam Pharmaceuticals,"Chicago, IL","Chicago, IL",amanda.garcia@alnylam.com,linkedin.com/in/amandagarcia,True,2022.0,Drug-induced liver injury prediction using spheroids,Series C,False,29,72,79
Dr. Susan Park,Principal Scientist - Toxicology,Merck,"Indianapolis, IN","Indianapolis, IN",susan.park@merck.com,linkedin.com/in/susanpark,True,2024.0,Predictive toxicology with in vitro systems,Seed,False,33,72,79
Dr. Thomas Chen,Director of Safety Sciences,Vertex Pharmaceuticals,"Chicago, IL","Chicago, IL",thomas.chen@vertex.com,linkedin.com/in/thomaschen,True,2022.0,Organ-on-chip technology in drug development,Series C,False,27,72,79
Dr. Andrew Lee,VP Safety Assessment,Bluebird Bio,"Philadelphia, PA","Philadelphia, PA",andrew.lee@bluebirdbio.com,linkedin.com/in/andrewlee,True,2022.0,High-throughput screening using 3D models,Series B,True,53,72,79
Dr. Andrew Miller,Senior Research Scientist,Novartis,"Cambridge, MA","Cambridge, MA",andrew.miller@novartis.com,linkedin.com/in/andrewmiller,True,2024.0,Microphysiological systems for toxicity prediction,Public,False,12,72,79
Dr. Maria Anderson,Senior Scientist - Hepatotoxicity,Alnylam Pharmaceuticals,"Cambridge, UK","Cambridge, UK",maria.anderson@alnylam.com,linkedin.com/in/mariaanderson,True,2024.0,Novel 3D hepatic models for DILI assessment,Series A,True,39,72,79
Dr. Christopher Park,Director of Toxicology,Editas Medicine,Remote - Texas,Remote - Texas,christopher.park@editasmedici.com,linkedin.com/in/christopherpark,True,2023.0,Organ-on-chip technology in drug development,Seed,True,42,72,79
Dr. Nancy Park,Senior Scientist - Hepatotoxicity,Sanofi,"Seattle, WA","Seattle, WA",nancy.park@sanofi.com,linkedin.com/in/nancypark,True,2023.0,Microphysiological systems for toxicity prediction,Series B,True,31,72,79
Dr. Nancy Park,Scientist II - Safety Assessment,Johnson & Johnson,Remote - Texas,Remote - Texas,nancy.park@johnson&john.com,linkedin.com/in/nancypark,True,2022.0,Novel 3D hepatic models for DILI assessment,Series C,True,36,72,79
Dr. Andrew Miller,Research Fellow,Johnson & Johnson,"Oxford, UK","Oxford, UK",andrew.miller@johnson&john.com,linkedin.com/in/andrewmiller,True,2023.0,3D cell culture models in safety pharmacology,Public,False,19,68,91
Dr. Thomas Brown,Senior Scientist - Hepatotoxicity,Sanofi,New Jersey,New Jersey,thomas.brown@sanofi.com,linkedin.com/in/thomasbrown,True,2023.0,High-throughput screening using 3D models,Public,False,22,68,91
Dr. Sarah Wilson,Safety Pharmacology Lead,Bluebird Bio,"Research Triangle Park, NC","Research Triangle Park, NC",sarah.wilson@bluebirdbio.com,linkedin.com/in/sarahwilson,True,2022.0,3D cell culture models in safety pharmacology,IPO,True,28,68,91
Dr. James Johnson,Senior Research Scientist,Novartis,"Cambridge, UK","Cambridge, UK",james.johnson@novartis.com,linkedin.com/in/jamesjohnson,True,2023.0,3D cell culture models in safety pharmacology,Public,False,48,68,91
Dr. Jennifer Wilson,Research Scientist II,Amgen,"San Francisco, CA","San Francisco, CA",jennifer.wilson@amgen.com,linkedin.com/in/jenniferwilson,True,2023.0,3D cell culture models in safety pharmacology,Public,False,35,68,91
Dr. Daniel Smith,Director of Toxicology,Johnson & Johnson,Remote - California,Remote - California,daniel.smith@johnson&john.com,linkedin.com/in/danielsmith,True,2022.0,Organ-on-chip technology in drug development,Public,True,50,68,91
Dr. Kevin Jones,Staff Scientist - DMPK,Merck,"Chicago, IL","Chicago, IL",kevin.jones@merck.com,linkedin.com/in/kevinjones,True,2023.0,Novel 3D hepatic models for DILI assessment,Series B,True,13,68,91
Dr. Nancy Miller,Senior Scientist - Hepatotoxicity,Bluebird Bio,"Chicago, IL","Chicago, IL",nancy.miller@bluebirdbio.com,linkedin.com/in/nancymiller,True,2024.0,Drug-induced liver injury prediction using spheroids,Series C,False,11,68,91
Dr. Daniel Mitchell,Research Scientist II,Alexion,"Philadelphia, PA","Philadelphia, PA",daniel.mitchell@alexion.com,linkedin.com/in/danielmitchell,True,2023.0,3D cell culture models in safety pharmacology,Series C,True,56,68,91
Dr. Matthew Martinez,Research Scientist II,Bluebird Bio,"San Francisco, CA","San Francisco, CA",matthew.martinez@bluebirdbio.com,linkedin.com/in/matthewmartinez,True,2024.0,3D cell culture models in safety pharmacology,Public,True,44,68,91
Dr. Jessica Chen,Senior Scientist - Hepatotoxicity,BioMarin,"Indianapolis, IN","Indianapolis, IN",jessica.chen@biomarin.com,linkedin.com/in/jessicachen,True,2023.0,Novel 3D hepatic models for DILI assessment,Series B,True,57,68,91
Dr. Jennifer White,Lead Toxicologist,Johnson & Johnson,"South San Francisco, CA","South San Francisco, CA",jennifer.white@johnson&john.com,linkedin.com/in/jenniferwhite,True,2022.0,Drug-induced liver injury prediction using spheroids,Series B,False,59,67,102
Dr. Robert Davis,Principal Investigator,Regeneron,"Cambridge, UK","Cambridge, UK",robert.davis@regeneron.com,linkedin.com/in/robertdavis,True,2022.0,Novel 3D hepatic models for DILI assessment,Series B,True,54,67,102
Dr. David Miller,Director of Toxicology,Gilead Sciences,New Jersey,New Jersey,david.miller@gileadscienc.com,linkedin.com/in/davidmiller,True,2022.0,3D cell culture models in safety pharmacology,Seed,False,11,64,104
Dr. Jessica Chen,Scientist II - Safety Assessment,Eli Lilly,"Boston, MA","Boston, MA",jessica.chen@elililly.com,linkedin.com/in/jessicachen,False,,,Series B,True,18,64,104
Dr. Sarah Davis,Senior Research Scientist,Alexion,"London, UK","London, UK",sarah.davis@alexion.com,linkedin.com/in/sarahdavis,True,2024.0,Predictive toxicology with in vitro systems,Series C,False,48,64,104
Dr. Michelle Moore,Research Scientist II,Ginkgo Bioworks,"Indianapolis, IN","Indianapolis, IN",michelle.moore@ginkgobiowor.com,linkedin.com/in/michellemoore,True,2023.0,Microphysiological systems for toxicity prediction,IPO,False,33,64,104
Dr. Lisa Miller,Associate Director - Safety,Amgen,"Basel, Switzerland","Basel, Switzerland",lisa.miller@amgen.com,linkedin.com/in/lisamiller,False,,,Series B,True,50,64,104
Dr. Nancy Park,Senior Research Scientist,Bluebird Bio,"Indianapolis, IN","Indianapolis, IN",nancy.park@bluebirdbio.com,linkedin.com/in/nancypark,True,2023.0,High-throughput screening using 3D models,Public,True,33,64,104
Dr. Daniel Mitchell,Scientist II - Safety Assessment,Takeda,"Basel, Switzerland","Basel, Switzerland",daniel.mitchell@takeda.com,linkedin.com/in/danielmitchell,False,,,Series C,True,49,64,104
Dr. Daniel Williams,Staff Scientist - DMPK,CRISPR Therapeutics,"Cambridge, UK","Cambridge, UK",daniel.williams@crisprtherap.com,linkedin.com/in/danielwilliams,True,2023.0,Organ-on-chip technology in drug development,Series A,True,8,64,104
Dr. Thomas White,Staff Scientist - DMPK,Novo Nordisk,"Philadelphia, PA","Philadelphia, PA",thomas.white@novonordisk.com,linkedin.com/in/thomaswhite,True,2024.0,Microphysiological systems for toxicity prediction,Public,False,20,64,104
Dr. Amanda Chen,Principal Investigator,Eli Lilly,"San Diego, CA","San Diego, CA",amanda.chen@elililly.com,linkedin.com/in/amandachen,True,2022.0,NAMs for hepatotoxicity screening,Public,True,23,63,113
Dr. David Mitchell,Principal Investigator,BioMarin,"Cambridge, UK","Cambridge, UK",david.mitchell@biomarin.com,linkedin.com/in/davidmitchell,True,2022.0,Novel 3D hepatic models for DILI assessment,Public,False,15,63,113
Dr. Christopher Thompson,Safety Pharmacology Lead,Regeneron,"Oxford, UK","Oxford, UK",christopher.thompson@regeneron.com,linkedin.com/in/christopherthompson,False,,,Series C,True,36,60,115
Dr. Kevin Brown,VP Safety Assessment,Bluebird Bio,"San Diego, CA","San Diego, CA",kevin.brown@bluebirdbio.com,linkedin.com/in/kevinbrown,False,,,Series C,True,45,60,115
Dr. Amanda Jones,Associate Director - Safety,Beam Therapeutics,"Cambridge, UK","Cambridge, UK",amanda.jones@beamtherapeu.com,linkedin.com/in/amandajones,False,,,Series C,True,20,60,115
Dr. Kevin Mitchell,Toxicology Manager,Beam Therapeutics,"Seattle, WA","Seattle, WA",kevin.mitchell@beamtherapeu.com,linkedin.com/in/kevinmitchell,False,,,Series B,True,14,60,115
Dr. Laura Miller,Associate Director - Safety,AbbVie,"Cambridge, UK","Cambridge, UK",laura.miller@abbvie.com,linkedin.com/in/lauramiller,False,,,Series C,False,11,60,115
Dr. Kevin Johnson,Senior Director - Nonclinical Safety,Vertex Pharmaceuticals,"Cambridge, UK","Cambridge, UK",kevin.johnson@vertex.com,linkedin.com/in/kevinjohnson,False,,,Series B,True,51,60,115
Dr. Nancy White,Head of Preclinical Safety,Moderna Therapeutics,"Cambridge, MA","Cambridge, MA",nancy.white@modernathera.com,linkedin.com/in/nancywhite,False,,,Public,False,46,60,115
Dr. Sarah Brown,Group Leader - Toxicology,Novo Nordisk,"Cambridge, MA","Cambridge, MA",sarah.brown@novonordisk.com,linkedin.com/in/sarahbrown,False,,,Public,False,18,60,115
Dr. Laura Garcia,Director of Safety Sciences,Bayer,"South San Francisco, CA","South San Francisco, CA",laura.garcia@bayer.com,linkedin.com/in/lauragarcia,False,,,Series B,True,32,60,115
Dr. Karen Wilson,Safety Pharmacology Lead,Johnson & Johnson,"San Francisco, CA","San Francisco, CA",karen.wilson@johnson&john.com,linkedin.com/in/karenwilson,False,,,Series B,True,56,60,115
Dr. Robert Johnson,Principal Scientist - Toxicology,Bluebird Bio,"Seattle, WA","Seattle, WA",robert.johnson@bluebirdbio.com,linkedin.com/in/robertjohnson,False,,,Series B,True,42,60,115
Dr. Karen Martin,Safety Pharmacology Lead,Moderna Therapeutics,"Boston, MA","Boston, MA",karen.martin@modernathera.com,linkedin.com/in/karenmartin,False,,,Public,False,9,60,115
Dr. Jessica Brown,Scientist II - Safety Assessment,Regeneron,"Cambridge, UK","Cambridge, UK",jessica.brown@regeneron.com,linkedin.com/in/jessicabrown,False,,,Series C,False,56,60,115
Dr. Maria Johnson,Senior Director - Nonclinical Safety,Merck,"South San Francisco, CA","South San Francisco, CA",maria.johnson@merck.com,linkedin.com/in/mariajohnson,False,,,Series C,False,44,60,115
Dr. Jennifer Park,Senior Director - Nonclinical Safety,Regeneron,"San Diego, CA","San Diego, CA",jennifer.park@regeneron.com,linkedin.com/in/jenniferpark,False,,,Series C,True,7,60,115
Dr. Andrew Harris,Associate Director - Safety,Bluebird Bio,"South San Francisco, CA","South San Francisco, CA",andrew.harris@bluebirdbio.com,linkedin.com/in/andrewharris,False,,,Series C,False,41,60,115
Dr. Nancy Mitchell,Research Fellow,Gilead Sciences,"Chicago, IL","Chicago, IL",nancy.mitchell@gileadscienc.com,linkedin.com/in/nancymitchell,True,2024.0,Predictive toxicology with in vitro systems,Series C,False,58,60,115
Dr. Nancy Miller,Senior Director - Nonclinical Safety,Gilead Sciences,"London, UK","London, UK",nancy.miller@gileadscienc.com,linkedin.com/in/nancymiller,False,,,Series C,False,37,60,115
Dr. Amanda Davis,Safety Pharmacology Lead,AstraZeneca,"San Francisco, CA","San Francisco, CA",amanda.davis@astrazeneca.com,linkedin.com/in/amandadavis,False,,,Series B,False,41,60,115
Dr. Jennifer Johnson,Group Leader - Toxicology,Regeneron,"Research Triangle Park, NC","Research Triangle Park, NC",jennifer.johnson@regeneron.com,linkedin.com/in/jenniferjohnson,True,2022.0,Drug-induced liver injury prediction using spheroids,Seed,False,22,60,115
Dr. Kevin Mitchell,Safety Pharmacology Lead,Alexion,"Boston, MA","Boston, MA",kevin.mitchell@alexion.com,linkedin.com/in/kevinmitchell,False,,,IPO,True,57,60,115
Dr. Betty Chen,Principal Investigator,Eli Lilly,"Research Triangle Park, NC","Research Triangle Park, NC",betty.chen@elililly.com,linkedin.com/in/bettychen,True,2022.0,3D cell culture models in safety pharmacology,IPO,False,44,59,136
Dr. Karen Park,Toxicology Manager,AbbVie,"Research Triangle Park, NC","Research Triangle Park, NC",karen.park@abbvie.com,linkedin.com/in/karenpark,False,,,Series B,True,13,56,137
Dr. Sarah Miller,Head of Preclinical Safety,Eli Lilly,Remote - Colorado,Remote - Colorado,sarah.miller@elililly.com,linkedin.com/in/sarahmiller,False,,,Series C,True,16,56,137
Dr. Thomas Jones,Group Leader - Toxicology,Editas Medicine,"London, UK","London, UK",thomas.jones@editasmedici.com,linkedin.com/in/thomasjones,False,,,Public,False,29,56,137
Dr. David Rodriguez,Head of Preclinical Safety,Bayer,"Seattle, WA","Seattle, WA",david.rodriguez@bayer.com,linkedin.com/in/davidrodriguez,False,,,Public,False,57,56,137
Dr. Amanda Martin,Safety Pharmacology Lead,Amgen,"San Francisco, CA","San Francisco, CA",amanda.martin@amgen.com,linkedin.com/in/amandamartin,False,,,Public,False,20,56,137
Dr. Kevin Thompson,Director of Safety Sciences,CRISPR Therapeutics,"Philadelphia, PA","Philadelphia, PA",kevin.thompson@crisprtherap.com,linkedin.com/in/kevinthompson,False,,,Series B,True,50,56,137
Dr. Jennifer Moore,VP Safety Assessment,Roche,Remote - Texas,Remote - Texas,jennifer.moore@roche.com,linkedin.com/in/jennifermoore,False,,,Series B,False,38,56,137
Dr. Brian Smith,Senior Director - Nonclinical Safety,Ginkgo Bioworks,"London, UK","London, UK",brian.smith@ginkgobiowor.com,linkedin.com/in/briansmith,False,,,Public,False,26,56,137
Dr. Jennifer Williams,Associate Director - Safety,AbbVie,"Chicago, IL","Chicago, IL",jennifer.williams@abbvie.com,linkedin.com/in/jenniferwilliams,False,,,Series B,True,10,56,137
Dr. Sarah Anderson,Group Leader - Toxicology,Gilead Sciences,"Chicago, IL","Chicago, IL",sarah.anderson@gileadscienc.com,linkedin.com/in/sarahanderson,False,,,Series C,False,14,56,137
Dr. Sarah Lee,Principal Scientist - Toxicology,AbbVie,"Seattle, WA","Seattle, WA",sarah.lee@abbvie.com,linkedin.com/in/sarahlee,False,,,Public,False,56,56,137
Dr. Jennifer Johnson,VP Safety Assessment,Sanofi,"Seattle, WA","Seattle, WA",jennifer.johnson@sanofi.com,linkedin.com/in/jenniferjohnson,False,,,Public,False,35,56,137
Dr. Michael Davis,Toxicology Manager,GSK,"Cambridge, UK","Cambridge, UK",michael.davis@gsk.com,linkedin.com/in/michaeldavis,False,,,Public,True,14,56,137
Dr. Robert Smith,Senior Director - Nonclinical Safety,Johnson & Johnson,"New York, NY","New York, NY",robert.smith@johnson&john.com,linkedin.com/in/robertsmith,False,,,Series C,True,8,56,137
Dr. Nancy Anderson,Director of Toxicology,AstraZeneca,"Indianapolis, IN","Indianapolis, IN",nancy.anderson@astrazeneca.com,linkedin.com/in/nancyanderson,False,,,Series B,True,46,56,137
Dr. Betty Chen,Head of Preclinical Safety,GSK,"Philadelphia, PA","Philadelphia, PA",betty.chen@gsk.com,linkedin.com/in/bettychen,False,,,Series B,True,49,56,137
Dr. Jennifer Young,Director of Toxicology,Intellia Therapeutics,"San Francisco, CA","San Francisco, CA",jennifer.young@intelliather.com,linkedin.com/in/jenniferyoung,False,,,Public,False,25,56,137
Dr. Robert Chen,Lead Toxicologist,GSK,"Cambridge, MA","Cambridge, MA",robert.chen@gsk.com,linkedin.com/in/robertchen,False,,,Series C,False,48,55,154
Dr. James Davis,Director of Toxicology,Sanofi,Remote - Texas,Remote - Texas,james.davis@sanofi.com,linkedin.com/in/jamesdavis,False,,,Public,False,11,52,155
Dr. Nancy Davis,Principal Scientist - Toxicology,Moderna Therapeutics,"Philadelphia, PA","Philadelphia, PA",nancy.davis@modernathera.com,linkedin.com/in/nancydavis,False,,,Public,True,21,52,155
Dr. Betty Martinez,Research Fellow,Sanofi,"San Diego, CA","San Diego, CA",betty.martinez@sanofi.com,linkedin.com/in/bettymartinez,True,2022.0,Advanced in vitro toxicity testing methods,Series B,False,56,52,155
Dr. James Mitchell,Group Leader - Toxicology,Bayer,"Philadelphia, PA","Philadelphia, PA",james.mitchell@bayer.com,linkedin.com/in/jamesmitchell,False,,,Public,True,35,52,155
Dr. Michael Williams,Research Fellow,CRISPR Therapeutics,"San Diego, CA","San Diego, CA",michael.williams@crisprtherap.com,linkedin.com/in/michaelwilliams,True,2022.0,Novel 3D hepatic models for DILI assessment,Series B,False,7,52,155
Dr. Kevin Rodriguez,Scientist II - Safety Assessment,Moderna Therapeutics,"Chicago, IL","Chicago, IL",kevin.rodriguez@modernathera.com,linkedin.com/in/kevinrodriguez,False,,,IPO,False,43,52,155
Dr. Susan Johnson,Senior Director - Nonclinical Safety,AbbVie,"Boston, MA","Boston, MA",susan.johnson@abbvie.com,linkedin.com/in/susanjohnson,False,,,Seed,False,37,52,155
Dr. Daniel Jones,Group Leader - Toxicology,Merck,Remote - Texas,Remote - Texas,daniel.jones@merck.com,linkedin.com/in/danieljones,False,,,Public,True,45,52,155
Dr. Brian Lee,Head of Preclinical Safety,GSK,"Research Triangle Park, NC","Research Triangle Park, NC",brian.lee@gsk.com,linkedin.com/in/brianlee,False,,,Public,False,42,52,155
Dr. Michael Brown,Senior Research Scientist,CRISPR Therapeutics,"Cambridge, UK","Cambridge, UK",michael.brown@crisprtherap.com,linkedin.com/in/michaelbrown,True,2022.0,Liver organoid applications in drug discovery,Series A,False,55,52,155
Dr. Michael Moore,Senior Director - Nonclinical Safety,GSK,"Chicago, IL","Chicago, IL",michael.moore@gsk.com,linkedin.com/in/michaelmoore,False,,,Public,True,30,52,155
Dr. Emily Miller,Director of Toxicology,AstraZeneca,Remote - Colorado,Remote - Colorado,emily.miller@astrazeneca.com,linkedin.com/in/emilymiller,False,,,Public,True,15,52,155
Dr. David Kumar,Principal Investigator,Vertex Pharmaceuticals,"Seattle, WA","Seattle, WA",david.kumar@vertex.com,linkedin.com/in/davidkumar,False,,,Series C,False,29,51,167
Dr. Amanda Lee,Lead Toxicologist,Editas Medicine,"Seattle, WA","Seattle, WA",amanda.lee@editasmedici.com,linkedin.com/in/amandalee,False,,,Series C,True,10,51,167
Dr. Jessica Harris,Research Fellow,Biogen,"Research Triangle Park, NC","Research Triangle Park, NC",jessica.harris@biogen.com,linkedin.com/in/jessicaharris,True,2022.0,NAMs for hepatotoxicity screening,Series B,True,46,48,169
Dr. Amanda Wilson,Research Scientist II,Eli Lilly,"New York, NY","New York, NY",amanda.wilson@elililly.com,linkedin.com/in/amandawilson,True,2022.0,3D cell culture models in safety pharmacology,Series B,False,56,48,169
Dr. James Anderson,Research Fellow,Novartis,"Cambridge, UK","Cambridge, UK",james.anderson@novartis.com,linkedin.com/in/jamesanderson,True,2022.0,NAMs for hepatotoxicity screening,IPO,False,52,48,169
Dr. Michelle Rodriguez,Senior Research Scientist,CRISPR Therapeutics,Remote - Texas,Remote - Texas,michelle.rodriguez@crisprtherap.com,linkedin.com/in/michellerodriguez,True,2022.0,Advanced in vitro toxicity testing methods,Series C,True,49,48,169
Dr. Sarah Kumar,Director of Safety Sciences,AstraZeneca,"South San Francisco, CA","South San Francisco, CA",sarah.kumar@astrazeneca.com,linkedin.com/in/sarahkumar,False,,,Seed,True,41,48,169
Dr. Jennifer Park,Safety Pharmacology Lead,Alnylam Pharmaceuticals,"Seattle, WA","Seattle, WA",jennifer.park@alnylam.com,linkedin.com/in/jenniferpark,False,,,Seed,True,40,48,169
Dr. Susan Jones,Research Fellow,Johnson & Johnson,"Research Triangle Park, NC","Research Triangle Park, NC",susan.jones@johnson&john.com,linkedin.com/in/susanjones,True,2022.0,Liver organoid applications in drug discovery,Series B,True,52,48,169
Dr. Amanda Young,Staff Scientist - DMPK,AstraZeneca,New Jersey,New Jersey,amanda.young@astrazeneca.com,linkedin.com/in/amandayoung,True,2022.0,Microphysiological systems for toxicity prediction,Public,True,36,48,169
Dr. Lisa Martin,Senior Director - Nonclinical Safety,Alexion,"San Francisco, CA","San Francisco, CA",lisa.martin@alexion.com,linkedin.com/in/lisamartin,False,,,Seed,False,38,48,169
Dr. Robert Taylor,Principal Investigator,GSK,New Jersey,New Jersey,robert.taylor@gsk.com,linkedin.com/in/roberttaylor,False,,,Public,False,44,47,178
Dr. Christopher Moore,Lead Toxicologist,Roche,"Oxford, UK","Oxford, UK",christopher.moore@roche.com,linkedin.com/in/christophermoore,False,,,IPO,True,60,47,178
Dr. Susan Rodriguez,Lead Toxicologist,GSK,"South San Francisco, CA","South San Francisco, CA",susan.rodriguez@gsk.com,linkedin.com/in/susanrodriguez,False,,,IPO,False,47,47,178
Dr. Thomas Kumar,Research Fellow,Bayer,"Basel, Switzerland","Basel, Switzerland",thomas.kumar@bayer.com,linkedin.com/in/thomaskumar,True,2022.0,Drug-induced liver injury prediction using spheroids,Seed,False,55,44,181
Dr. Brian Kumar,Head of Preclinical Safety,Johnson & Johnson,"Research Triangle Park, NC","Research Triangle Park, NC",brian.kumar@johnson&john.com,linkedin.com/in/briankumar,False,,,Seed,True,10,44,181
Dr. Kevin Taylor,Staff Scientist - DMPK,Moderna Therapeutics,"Basel, Switzerland","Basel, Switzerland",kevin.taylor@modernathera.com,linkedin.com/in/kevintaylor,False,,,Series C,True,41,40,183
Dr. David Williams,Senior Research Scientist,GSK,"Cambridge, MA","Cambridge, MA",david.williams@gsk.com,linkedin.com/in/davidwilliams,False,,,IPO,False,37,36,184
Dr. Thomas Lee,Research Scientist II,BioMarin,"Oxford, UK","Oxford, UK",thomas.lee@biomarin.com,linkedin.com/in/thomaslee,False,,,Series C,False,51,36,184
Dr. David Wilson,Principal Investigator,Johnson & Johnson,"New York, NY","New York, NY",david.wilson@johnson&john.com,linkedin.com/in/davidwilson,False,,,Seed,False,27,35,186
Dr. Betty Moore,Senior Scientist - Hepatotoxicity,Biogen,Remote - Colorado,Remote - Colorado,betty.moore@biogen.com,linkedin.com/in/bettymoore,False,,,Series A,False,43,32,187
Dr. Michael Martinez,Senior Research Scientist,Moderna Therapeutics,"Research Triangle Park, NC","Research Triangle Park, NC",michael.martinez@modernathera.com,linkedin.com/in/michaelmartinez,False,,,Series C,True,27,32,187
Dr. Betty Park,Staff Scientist - DMPK,Alnylam Pharmaceuticals,Remote - California,Remote - California,betty.park@alnylam.com,linkedin.com/in/bettypark,False,,,Series B,False,29,32,187
Dr. Susan Thompson,Staff Scientist - DMPK,AstraZeneca,Remote - California,Remote - California,susan.thompson@astrazeneca.com,linkedin.com/in/susanthompson,False,,,Series C,False,22,32,187
Dr. Susan Young,Research Scientist II,Novartis,"San Francisco, CA","San Francisco, CA",susan.young@novartis.com,linkedin.com/in/susanyoung,False,,,Public,False,52,32,187
Dr. Laura Williams,Research Fellow,Editas Medicine,New Jersey,New Jersey,laura.williams@editasmedici.com,linkedin.com/in/laurawilliams,False,,,Public,True,32,32,187
Dr. Thomas Garcia,Staff Scientist - DMPK,Takeda,"Seattle, WA","Seattle, WA",thomas.garcia@takeda.com,linkedin.com/in/thomasgarcia,False,,,Public,True,9,32,187
Dr. Brian Martinez,Senior Research Scientist,Eli Lilly,"Chicago, IL","Chicago, IL",brian.martinez@elililly.com,linkedin.com/in/brianmartinez,False,,,Series C,False,58,32,187
Dr. Matthew Davis,Senior Research Scientist,Eli Lilly,"Chicago, IL","Chicago, IL",matthew.davis@elililly.com,linkedin.com/in/matthewdavis,False,,,Public,False,19,28,195
Dr. Maria Martinez,Senior Scientist - Hepatotoxicity,Alnylam Pharmaceuticals,Remote - Texas,Remote - Texas,maria.martinez@alnylam.com,linkedin.com/in/mariamartinez,False,,,Public,True,26,28,195
Dr. Matthew Smith,Research Scientist II,AbbVie,Remote - Texas,Remote - Texas,matthew.smith@abbvie.com,linkedin.com/in/matthewsmith,False,,,Public,False,43,28,195
Dr. Christopher Harris,Research Fellow,Merck,"Philadelphia, PA","Philadelphia, PA",christopher.harris@merck.com,linkedin.com/in/christopherharris,False,,,Public,False,28,28,195
Dr. Brian Davis,Senior Research Scientist,Merck,Remote - California,Remote - California,brian.davis@merck.com,linkedin.com/in/briandavis,False,,,Public,False,53,28,195
Dr. Robert Young,Senior Research Scientist,AbbVie,Remote - Texas,Remote - Texas,robert.young@abbvie.com,linkedin.com/in/robertyoung,False,,,Public,False,52,28,195
